US giant, Eli Lilly launched Mounjaro (tirzepatide) which is a prescription medicine for adults with type 2 diabetes used ...

According to TipRanks, JNJ stock has received a Moderate Buy consensus rating, with five Buys and eight Holds assigned in the last three months. The average share price target for JNJ is $168.27, ...

Copycat versions of Eli Lilly's diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They're ...

Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.

LCGC International spoke with Daniel Meston and Dwight Stoll from Gustavus Adolphus College in St. Peter, Minnesota, USA, ...

Johnson & Johnson Chairman and CEO Joaquin Duato says “our increased U.S. investment begins with the ground-breaking of a ...

Johnson & Johnson says it will invest more than $55 billion within the United States over the next four years, including four ...

Johnson & Johnson follows Eli Lilly in spending billions on U.S. manufacturing after President Donald Trump threatened major ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India, marking its entry into a rapidly growing market.

The other five KY innovation hubs are: Awesome Inc (Lexington); Blue North (Covington); Central Region Ecosystem for Arts, ...

(Reuters) - Johnson & Johnson plans to spend more than $55 billion to build four plants in the U.S. over the next four years, ...

Ovarian cancer (OC) is the fifth most common cause of cancer-related mortality worldwide and represents the leading cause of death for gynecological malignancies. Nevertheless, over the last years, ...